Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Teradata Corporation ( TDC - Analyst Report ) recently announced that Blue Cross and Blue Shield of Minnesota, a nonprofit independent licensee of the Blue Cross and Blue Shield Association, will be supported by Teradata’s data warehouse appliance and professional services.
Blue Cross expects that the Teradata platform will enable it to improve customer satisfaction, as the quality of information will improve, which in turn will enable it to improve the quality of its services and also introduce new services where relevant. Additionally, it expects improvements in insurance claim processing costs and time, which could help generate additional business for the company.
Teradata, with its consulting services and tools, will help Blue Cross offer healthcare administration and IT operations more cost effectively, without disrupting operations during installation. It will also provide important and efficient data that would support business strategy and solve critical problems, thereby providing improved health care services to Blue Cross members.
In our view, the data warehousing market is mature and has been dominated by large players like Oracle Corp. ( ORCL - Analyst Report ) , International Business Machines Corp. ( IBM - Analyst Report ) , Microsoft Corp. ( MSFT - Analyst Report ) , Sybase and SAP AG ( SAP - Analyst Report ) . Teradata is up against increasing competition from larger players in the data warehousing industry, which is leading to market share erosion. These large technology vendors have greater resources for increased technology investments, resulting in lower sales at Teradata. As a result, Teradata will continue to face severe pricing pressure, which may be expected to hurt its margins.
But, we expect synergies from acquisitions, improved traction from sales force expansion, new products and alliances, market share gains and a growing database analytics market to act as tailwinds for the company.
Although we maintain our long-term Neutral rating, we currently have a Zacks #4 Rank for Teradata Corp., which implies a Sell rating in the short term (1-3 months)
Read the full reports :
Analyst Report on MSFT
Analyst Report on IBM
Analyst Report on SAP
Analyst Report on TDC
Analyst Report on ORCL